|
Keratitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting IL-17A and/or the OPG/RANKL/RANK/TRAIL system is a potential therapeutic strategy in controlling the outcome of <i>P. aeruginosa</i> keratitis, which was demonstrated by concurrent topical application of IL-17A-neutralizing Ab and ciprofloxacin in B6 mice.
|
31767781 |
2020 |
|
Alcohol Use Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
This may contribute to alcohol associated negative affect and suggest potential therapeutic benefit of TRAIL inhibition in AUD.
|
30610351 |
2019 |
|
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
In an orthotopic mouse model of TRAIL-resistant ATC, treatment with MADD siRNA alone reduced tumor growth that, when combined with TRAIL, resulted in significant tumor regressions.
|
30999276 |
2019 |
|
Scleroderma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in α-SMA<sup>+</sup> MFBs is a viable therapy for fibrosis in scleroderma.
|
30850660 |
2019 |
|
Fenestration (morphologic abnormality)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fenestrations are reorganized in response to nicotinamide mononucleotide, sildenafil, amlodipine, and TNF-related apoptosis-inducing ligand.
|
30285464 |
2019 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, multiple clinical studies have identified TRAIL or DR5 as biomarkers in the prediction of severity and mortality following myocardial infarction and in heart failure development risk suggesting a role of DR5 signaling in the heart.
|
31473246 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, multiple clinical studies have identified TRAIL or DR5 as biomarkers in the prediction of severity and mortality following myocardial infarction and in heart failure development risk suggesting a role of DR5 signaling in the heart.
|
31473246 |
2019 |
|
Hyperprolactinemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The treatment induced mild hyperprolactinemia and increased TRAIL expression on NKC as well as the secretion of IL-1ra, IL-2, PDGF and IFN-γ.Viral loads decreased in six HCVp.
|
30520386 |
2019 |
|
Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Here we will review the actions of TRAIL, OPG, and TWEAK on diabetic and non-diabetic kidney disease, in order to provide insights into their full clinical potential as biomarkers and/or therapeutic options against kidney disease.
|
31097613 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis.
|
31045578 |
2019 |
|
Stress, Psychological
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, the results confirmed that the FasL/Fas system played an important role in the psychological stress-induced apoptosis of spermatozoa and spermatogenic cells and that FasL triggered sperm apoptosis in epididymis dependently through promoting TNF-α and TRAIL secretion.
|
31066896 |
2019 |
|
Trigeminal Neuralgia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two proteins seemed to be of specific interest for TN: TRAIL and TNF-β.
|
31373951 |
2019 |
|
Viral hepatitis
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, studies on the role of TRAIL in liver injury have reported that TRAIL plays an essential role in viral hepatitis, fatty liver diseases, etc.
|
30544063 |
2019 |
|
Malignant neoplasm of penis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our in vitro experiments suggested CASP8 was involved in mediating TRAIL-induced apoptosis of penile cancer cell lines.
|
31034097 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis.
|
31045578 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
This suggests TRAIL-based approaches as potential therapeutic options for brain-metastatic breast cancer.
|
30266755 |
2019 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma.
|
30809285 |
2019 |
|
Acute HIV infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because the TRAIL pathway has been implicated in CD4 T cell death occurring during HIV-1 infection, we used short hairpin RNA knockdown, CRISPR deletion, or Abs specific for TRAILshort to determine the effect of inhibiting TRAILshort on the outcome of experimental acute HIV infection in vitro.
|
31189571 |
2019 |
|
Penis carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our in vitro experiments suggested CASP8 was involved in mediating TRAIL-induced apoptosis of penile cancer cell lines.
|
31034097 |
2019 |
|
Cirrhosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
|
30544063 |
2019 |
|
HER2-positive carcinoma of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
|
30928382 |
2019 |
|
Adult Penile Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our in vitro experiments suggested CASP8 was involved in mediating TRAIL-induced apoptosis of penile cancer cell lines.
|
31034097 |
2019 |
|
Immunosuppression
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Based on our analysis, we revealed that the key factors (e.g.WNT5A, TRAIL, CSF1, etc.) mediated the activation of PC-Treg and PC-TAM interaction pathways, which induced the immunosuppression during CRPC progression.
|
31504033 |
2019 |
|
High-Risk Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This is the first study to demonstrate that XN alters the expression of DR5 as well as the synergistic effect of XN on TRAIL in NB and provides a strong rationale for further preclinical analysis.
|
30870485 |
2019 |
|
Angina Pectoris
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
At baseline, lower TRAIL level was associated with more coronary artery calcium (OR = 1.2 per SD, 95%CI 1.1-1.5, p = 0.02), and with history of myocardial infarction (OR = 2.3 per SD, 95%CI 1.2-4.5, p = 0.02), angina (OR = 1.6 per SD, 95%CI 1.1-2.6, p = 0.03), and angioplasty (OR = 1.8 per SD, 95%CI 1.0-3.1, p = 0.04) in models adjusted for cardiovascular risk-factors, FEV<sub>1</sub>, and emphysema.
|
30509711 |
2018 |